Clinical Trials

About this page

This section of the website is used to post information about relevant clinical trials in Canada as we are made aware of them. At the Foundation, we recommend you ask your doctor whether there are any clinical trials going on that you may be able to join. This has two benefits: firstly, you will have the opportunity to try new drugs that, hopefully, will come on the market and which may help you; and secondly, you are contributing to important research and that will make you feel good.

Clinical Trials and Drug Safety in Canada

Why Participate in a Clinical Trial

Dr. Gerard (Gerry) Cox talks briefly about what a clinical trial is, how a clinical trial is run, generally what drugs are being tested for IPF, and why you should participate in a clinical trial. The video is a recording of an interview with Dr. Cox shown to high school students from Hamilton, Ontario on December 2nd, 2013.

Clinical Trials in Canada

If you become aware of a relevant clinical trial for pulmonary fibrosis patients, please contact us at news.cpff@gmail.com and we will add it here.

Partitioned Training of Patients With IPF
Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT03752892

Idiopathic pulmonary fibrosis (IPF) is a lung disease that limits the ability to breathe enough for a good workout. One way to improve the exercise training is to reduce the number of muscles being trained together. By training one leg at a time, the patient does not have to breathe as much allowing each leg a better workout. Our groundwork suggests it may work in patients with IPF. This study will help decide whether one-legged exercise training is better at improving a patient’s exercise endurance compared to the usual way of exercising with both legs at the same time.

Study Locations as of March 18, 2019:  (Recruiting) West Park Healthcare Centre, Toronto, ON  M6M 2J5

Molecular Diagnosis of IIPs: a Prospective Study
Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study

Molecular diagnosis of idiopathic interstitial pneumonias is an innovative way to potentially improve the diagnostic accuracy of surgical lung biopsies (SLBs), introducing molecular classifiers of idiopathic pulmonary fibrosis (IPF) vs. non-specific interstitial pneumonia (NSIP), the 2 main types of idiopathic interstitial pneumonias (IIPs).

ClinicalTrials.gov Identifier: NCT03836417

Study Locations as of May 15, 2019:  (Recruiting) London Health Science Centre, London, ON  N6A 5W9

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With IPF
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis – Phase 2

ClinicalTrials.gov Identifier: NCT03142191

Study Locations as of June 11, 2019:  (Recruiting) Kelowna & Respiratory Allergy Clinic, Kelowna, BC  V1W 1V3; The Lung Centre Respiratory Clinic – Vancouver General Hospital Location, Vancouver, BC  V5Z 1M9  (Not yet recruiting) Dr. Syed Anees Medicine Professional Corporation, Windsor, ON  N8X 1T3

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With IPF When Used Together With Standard of Care
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA2) – Phase 3

ClinicalTrials.gov Identifier: NCT03733444

Study Locations as of May 20, 2019:  (Recruiting) Dr Anil Dhar Professional Medicine Corporation,
Windsor, ON  N8W1L9

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With IPF
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis – Phase 2

ClinicalTrials.gov Identifier: NCT03287414

Study Locations as of March 25, 2019:  (Recruiting) Novartis Investigative Site, QC  GIV 4G5

Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF (SCENIC) – Phase 2b

ClinicalTrials.gov Identifier: NCT03864328

Study Locations as of March 8, 2019:  (Not yet recruiting) St. Paul’s Hospital, Vancouver, BC; University of Calgary, Calgary, AB; University of Alberta, Edmonton, AB; McMaster University, Hamilton, ON; University Health Network, Toronto General Hospital, Toronto, ON; Centre Hospitalier Universitaire de Montreal, Montréal, PC; Dalhousie University, Halifax, NS

Nebulized Fentanyl in Patients With Mild to Moderate IPF and Chronic Dyspnea
Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea – Phase 3

ClinicalTrials.gov Identifier: NCT03018756

Study Locations as of September 25, 2018:  (Recruiting) Queen’s University, Kingston, ON

Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis
Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT02632123

Study Locations as of November 7, 2018:  (Recruiting) London Health Science Centre, London, ON

High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib (HOPE-IPF)
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib (HOPE-IPF)

ClinicalTrials.gov Identifier: NCT02551068

Study Locations as of May 23, 2019:

(Recruiting) UBC Okanagan Kelowna, BC; St. Paul’s Hospital, Vancouver, BC; University of Calgary, Calgary, AB; McMaster University, Hamilton, ON;  Queen’s University, Kingston, ON; McGill University, Montreal, QC; Laval University, Quebec City, QC

The following studies are not recruiting participants – Active or Completed.

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced IPF and Risk of Group 3 Pulmonary Hypertension
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension – Phase 2

ClinicalTrials.gov Identifier: NCT02951429

Study Locations as of May 6, 2019: Active but not recruiting participants.

A Study to Characterize the Disease Behavior of IPF and ILD During the Peri-Diagnostic Period
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

ClinicalTrials.gov Identifier: NCT03261037

Study Locations as of April 11, 2019:    Active, but not recruiting participants.

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in IPF Patients With Advanced Lung Function Impairment
Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment – Phase 3

ClinicalTrials.gov Identifier: NCT02802345

Study Locations as of January 11, 2019:  Completed. Has results.

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis – Phase 3

ClinicalTrials.gov Identifier: NCT01619085

Study Locations as of April 30, 2019:  Active but not recruiting participants. Has results.

Evaluate the Safety and Efficacy of FG-3019 in Patients With IPF
Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis – Phase 2

ClinicalTrials.gov Identifier: NCT01890265

Study Locations as of May 3, 2019:  Completed.

The following studies are not recruiting participants – Active or Completed.

Efficacy and Safety of Nintedanib
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) – Phase 3

ClinicalTrials.gov Identifier: NCT02999178

Study Locations as of May 15, 2019:  Active but not recruiting participants.

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease – Phase 2

ClinicalTrials.gov Identifier: NCT03099187

Study Locations as of May 29, 2019:  Active but not recruiting participants.

The following studies are not recruiting participants – Active org Completed.

Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis – Phase 3

ClinicalTrials.gov Identifier: NCT02597933

Study Locations as of December 7, 2018:  Completed. Boehringer Ingelheim May 20, 2019 release results